摘要：

2-aryl-substituted imidazo[5,1-][1,2,4]triazin-4(3)-ones represent a new class of potent cGMP-PDE 5 inhibitors that prove to be superior to other purine-isosteric inhibitors. Subnanomolar inhibitors of PDE 5 with activity in in vivo models for erectile dysfunction have been identified. BAY 38-9456 (Vardenafil-hydrochloride) has been selected for clinical studies in the indication of erectile dysfunction.2-aryl substituted imidazo[5,1-][1,2,4]triazin-4(3)-ones represent a new class of potent cGMP-PDE inhibitors which proves to be superior to other purine-isosteric inhibitors. Subnanomolar and orally bioavailable inhibitors of PDE 5 have been identified. BAY 38-9456 (Vardenafil* HCl) is currently being evaluated in clinical studies for the indication erectile dysfunction.

展开